264
Participants
Start Date
November 30, 2013
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
Meningococcal B Recombinant vaccine rMenB+OMV NZ
Subjects were randomized to one of two treatment groups to receive intramuscular (IM) vaccination with two doses of rMenV+OMV NZ vaccine (0.5 mL) in the non-dominant arm, one month apart. Subjects were followed for two months.
Placebo
Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
Meningococcal ACWY-CRM conjugate vaccine
Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
06 Kosin University Gospel Hospital 34, amnam-dong, Seo-gu
05 YuKorea University Ansan Hospital 23, Jeokgeum-ro, Danwon-gu, Ansan-si
04 Pusan National University Yangsan Hospital 20 Geumo-ro, Mulgeum-eup, Yangsan
07 Seoul National University Bundang Hospital 82, Gumi-ro 173 Beon-gil, Bundang-gu
01 Seoul National University Hospital 101 Daehang-ro,, Jongno-gu
03 Ewha Womans University Mokdong Hospital, Department of Pediatrics, 911-1 Mokdong, Yangch’ŏn-gu
02 Inha University Hospital 7-206, 3rd street, Shinheung-dong, Jung-gu, Incheon
Lead Sponsor
Collaborators (1)
Novartis
INDUSTRY
Novartis Vaccines
INDUSTRY